Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
Clinical trial NCT06884254 · WITHDRAWN
Trial details
- NCT number
- NCT06884254
- Sponsor
- EirGenix, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-01
- Primary completion
- 2026-11-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.